Mezoo Pursues KOSDAQ Listing with Mobile Remote Patient Monitoring Platform

Mezoo, a mobile remote patient monitoring company, announced on March 9 that it will hold a corporate briefing and pursue a listing on KOSDAQ.

Mezoo is a digital healthcare company founded in 2007 by biomedical engineering PhDs from Yonsei University, Wonju Campus. The company possesses core competitiveness in precision measurement technology for biosignals and on-device biosignal processing technology. Mezoo has established an integrated technological system that covers everything from biosignal measurement and analysis to product design and manufacturing in-house. Based on this, Mezoo has secured commercial references in the mobile remote patient monitoring sector and pioneered a market focused on clinical settings.

Mezoo's mobile remote patient monitoring platform, "HiCardi," was developed to address these limitations. HiCardi aims to expand the conventional monitoring system, which has been centered on intensive care units, to general wards and patient transfer environments, enabling continuous patient monitoring throughout the hospital. Designed with a wearable structure, HiCardi can be used in various clinical scenarios, including inpatient wards, patient transportation, and post-discharge home monitoring.

The HiCardi platform is an integrated monitoring system consisting of a smart patch, mobile application, and central control software. In particular, HiCardi Plus is the first wearable combination medical device in Korea to integrate a patient monitor and Holter function into a single device and has received approval from the Ministry of Food and Drug Safety (MFDS). The smart patch features on-device technology that enables real-time analysis of biosignals, allowing for both continuous monitoring and immediate detection of abnormal signs. Notably, the smart patch is designed with defibrillation protection, enabling defibrillation procedures without removing the device in emergencies. Leveraging this technological edge, Mezoo has secured major medical device certifications such as MFDS, CE, FDA, and ANVISA in nine countries, including the United States, Europe, South America, the Middle East, and Southeast Asia.

HiCardi has expanded its commercial references based on real-world use in medical settings. Currently, it has been adopted by approximately 53% of the 47 tertiary hospitals in Korea and is in use at more than 700 hospitals and clinics nationwide. Hospitals can apply health insurance reimbursement for patient monitoring operations using HiCardi, such as ECG bed monitoring (E6544) or monitoring through remote heart rate technology, providing a foundation for continuous monitoring even in general wards. This serves as one of the factors linking technology adoption to actual operational systems. Additionally, Mezoo is working with Dong-A ST, a strategic investor and HiCardi’s domestic hospital distribution partner, to drive a market expansion strategy leveraging a nationwide hospital network. Through a collaborative model utilizing Dong-A ST's sales network, Mezoo has rapidly secured commercial references in major domestic medical institutions within just three years of product launch.

Mezoo is also developing next-generation products, building on its established references in clinical settings. The multi-parameter patient monitoring device currently under development aims to integrate the measurement of various vital signs—including multi-channel ECG-based heart rate, arrhythmia, respiration, core body temperature, oxygen saturation, and continuous blood pressure—into a single device, with some features already undergoing clinical trials. With the KOSDAQ listing as a catalyst, Mezoo plans to strengthen joint marketing efforts with Dong-A ST to further solidify its position in Korea's mobile patient monitoring market. Moreover, the company is considering expanding into home-based patient management models (home hospital) and wellness sectors, leveraging its experience accumulated in hospital-centered medical services. Mezoo will also gradually enhance its domestic and global marketing capabilities. In Korea, the company will reinforce its customer base by expanding specialized teams capable of installation, training, and clinical support, while internationally, it plans to secure local experts in key markets to implement sales strategies tailored to each country’s healthcare system.

Through this listing, Mezoo plans to issue 1,345,000 new shares to the public. The expected offering price ranges from KRW 16,700 to KRW 21,600, with the total expected offering amounting to approximately KRW 22.5 billion to KRW 29.1 billion. The institutional investor book-building is scheduled for March 5 to 11, while the public subscription will take place on March 16 and 17. The lead underwriter for the listing is Shinhan Investment Corp.

A significant portion of the funds raised will be used to build distribution networks and support local sales, marketing, technical demonstrations, and joint research focused on advanced overseas markets such as North America and Europe. Additionally, capital secured through the listing will be invested in research and development (R&D) to advance AI-based predictive and diagnostic technologies and to recruit key talent. In particular, the company will use the funds for clinical trials of next-generation products and joint research with leading hospitals in Europe, further strengthening its technological competitiveness.

Jungwhan Park, CEO of Mezoo, said, "With this listing as an opportunity, we will combine data-driven predictive and diagnostic technologies with clinical experience to expand our digital healthcare model—validated in Korea’s medical field—into the global healthcare market."

This content was produced with the assistance of AI translation services.